by Madaline Spencer | Jun 13, 2025
The U.S. Food and Drug Administration (FDA) has approved taletrectinib for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). ROS1-positive NSCLC is a rare and aggressive lung cancer that typically occurs in...
by Madaline Spencer | Jun 10, 2025
Nate Milam II, Patient Advocate for the Histiocytosis Association, discusses his diagnostic odyssey with histiocytosis. Histiocytosis is a rare hematologic disorder characterized by the overproduction of histiocytes, a type of white blood cell. In people...
by Madaline Spencer | May 16, 2025
The U.S. Food and Drug Administration (FDA) approved Welireg (belzutifan) for patients ages 12 years and older with locally advanced, unresectable or metastatic pheochromocytoma or paraganglioma. Pheochromocytoma and paraganglioma are rare tumors that develop from...
by Madaline Spencer | Apr 29, 2025
The U.S. Food and Drug Administration (FDA) has approved nivolumab plus ipilimumab for first-line therapy in adult patients with unresectable or metastatic hepatocellular carcinoma (HCC). HCC is a rare carcinoma of the liver characterized by nodules occurring anywhere...
by Madaline Spencer | Apr 17, 2025
A recent study published in The Journal of Clinical Endocrinology & Metabolism analyzed the use of digital voice analysis as a biomarker of acromegaly. Acromegaly is an endocrine disorder resulting from the overproduction of growth hormone in the pituitary gland....
